Treatment Information

Back

Prostate Cancer treatment details. Chemotherapy.

University of Southern California, Los Angeles CA, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Los Angeles CA
Treatments:ChemotherapyHospital:University of Southern California
Drugs:Journal:Link
Date:Nov 2005

Description:

Patients: This Phase II study involves 29 men with advanced metastatic hormone refractory prostate cancer. The median age was 73 years. Metastatic sites include bone, lymph node, liver, and lung.

Treatment: The treatment consisted of three agents: tesmilifene which is a chemo-potentiator (a small molecule which boosts activity of standard cytotoxic agents such as anthracyclines), mitoxantrone (a chemotherapy drug), and prednisone (a corticosteroid).

Toxicity: Grade 3-4 toxicities included leucopenia, agitation, akathesia, confusion, hallucinations, asthenia, nausea, vomiting, anorexia, myasthenia, insomnia, constipation, dehydration, leucopenia, thrombocytopenia, bone pain, depression and hypotension.

Results: The median overall survival was 10.8 months. The two-year survival rate was 21%.

Correspondence: D. Raghavan




Back